A practical reference on reversed-phase HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-03 and is reviewed periodically as new material appears.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.
Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised solid form |
| Solubility class | Freely soluble in water | Hydrophilic heptapeptide |
| Dry storage temperature | -20 degrees Celsius or lower | Sealed, desiccated, protected from light |
| Solution storage | 2 to 8 degrees Celsius short term | Avoid repeated freeze-thaw cycles |
| Common identification method | Reversed-phase HPLC with mass spectrometry | Confirms purity and molecular mass |
Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.
Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
=== Pro-101-2 (diabetic foot ulcers) === Pro-101-2 is a topical PDGF-BB gel candidate for the treatment of DFUs. The company received IND approval from NMPA in July 2021 and completed Phase I clinical trials in October 2021. The Phase II clinical trial was initiated in February 2022, with the first patient enrolled in December 2024. As of 31 December 2025, the Phase II trial was ongoing in China.
In 1993, the FDA issued a document for the content limits of DON in food and animal feed at an advisory level. In 2003, US published a patent that is very promising for farmers to produce a trichothecene-resistant crop. Zearalenone Zearalenols
Burmese tofu (to hpu in Burmese) is a legume product made from besan (chana dal) flour; the Shan variety uses yellow split pea flour instead. Both types are yellow in color and generally found only in Myanmar, and Yunnan province of China, though the Burman variety is also available in some overseas restaurants serving Burmese cuisine. The term is believed to be derived from Dou Fen (bean Jelly) from Chinese and it was adopted to Burmese cuisine through Shan people (Dai people of Yunnan) . Burmese tofu may be fried as fritters cut into rectangular or triangular shapes. A variety called hsan to hpu (or hsan ta hpo in Shan regions) is made from rice flour (called hsan hmont or mont hmont) and is white in color with the same consistency as yellow Burmese tofu when set. It is eaten as a salad in the same manner as yellow tofu.
==== Military service (1954–55) ==== With the Korean War occurring, Mizell had been drafted to serve in the United States Army as early as 1952, but he managed to get his service deferred twice because he was the support for his mother and grandmother. Finally, shortly after the 1953 season ended, he reported to Fort McPherson, Georgia, where he would be stationed for the next two years. Mizell, who walked with a "two-furrow" stride, had to make a special effort not to step on the heels of the soldier in front of him when he was marching in ranks. He saw no combat, instead winning 36 games (with only two losses) for the fort's baseball team. Mizell threw four no-hitters and 16 shutouts, helping the team reach the Army baseball championship tournament at Fort Belvoir, Virginia, in 1955. A sergeant by the time he was discharged, Mizell had struck out 324 batters in two years of service.
Sources: en.wikipedia.org
In 1952, L. V. Radushkevich and V. M. Lukyanovich published clear images of 50-nanometre diameter tubes made of carbon in the Journal of Physical Chemistry of Russia. This discovery was largely unnoticed, as the article was published in Russian, and Western scientists' access to Soviet press was limited during the Cold War. Monthioux and Kuznetsov mentioned in their Carbon editorial: The fact is, Radushkevich and Lukyanovich [...] should be credited for the discovery that carbon filaments could be hollow and have a nanometre-size diameter, that is to say for the discovery of carbon nanotubes. In 1976, Morinobu Endo of CNRS observed hollow tubes of rolled up graphite sheets synthesised by a chemical vapour-growth technique. The first specimens observed would later come to be known as single-walled carbon nanotubes (SWNTs). Endo, in his early review of vapor-phase-grown carbon fibers (VPCF), also reminded us that he had observed a hollow tube, linearly extended with parallel carbon layer faces near the fiber core. This appears to be the observation of multi-walled carbon nanotubes at the center of the fiber. Mass-produced MWCNTs are strongly related to the VPGCF developed by Endo. In fact, they call it the "Endo process", out of respect for his early work and patents. In 1979, John Abrahamson presented evidence of carbon nanotubes at the 14th Biennial Conference of Carbon at Pennsylvania State University. The conference paper described carbon nanotubes as carbon fibers that were produced on carbon anodes during arc discharge.
The coexistence of various non-enzymatically replicating sequences could help to maintain a sufficient diversity of RNA modules used later to build molecules with catalytic functions. From the mathematical point of view, it is possible to find conditions required for cooperation of several hypercycles. However, in reality, the cooperation of hypercycles would be extremely difficult, because it requires the existence of a complicated multi-step biochemical mechanism or an incorporation of more than two types of molecules. Both conditions seem very improbable; therefore, the existence of coupled hypercycles is assumed impossible in practice. Evolution of a hypercycle ensues from the creation of new components by the mutation of its internal species. Mutations can be incorporated into the hypercycle, enlarging it if, and only if, two requirements are satisfied. First, a new information carrier Inew created by the mutation must be better recognized by one of the hypercycle's members Ii than the chain Ii+1 that was previously recognized by it. Secondly, the new member Inew of the cycle has to better catalyse the formation of the polynucleotide Ii+1 that was previously catalysed by the product of its predecessor Ii. In theory, it is possible to incorporate into the hypercycle mutations that do not satisfy the second condition. They would form parasitic branches that use the system for their own replication but do not contribute to the system as a whole.
In 2018, the DeepMind Safety team outlined AI safety problems in specification, robustness, and assurance. The following year, researchers organized a workshop at ICLR that focused on these problem areas. In 2021, Unsolved Problems in ML Safety was published, outlining research directions in robustness, monitoring, alignment, and systemic safety. In 2023, Rishi Sunak said he wants the United Kingdom to be the "geographical home of global AI safety regulation" and to host the first global summit on AI safety. The AI safety summit took place in November 2023, and focused on the risks of misuse and loss of control associated with frontier AI models. During the summit, the intention to create the International Scientific Report on the Safety of Advanced AI was announced. In 2024, The US and UK forged a new partnership on the science of AI safety. The MoU was signed on 1 April 2024 by US commerce secretary Gina Raimondo and UK technology secretary Michelle Donelan to jointly develop advanced AI model testing, following commitments announced at an AI Safety Summit in Bletchley Park in November. In 2025, an international team of 96 experts chaired by Yoshua Bengio published the first International AI Safety Report. The report, commissioned by 30 nations and the United Nations, represents the first global scientific review of potential risks associated with advanced artificial intelligence.
Isothermal titration calorimetry (ITC), is considered as the most quantitative technique available for measuring the thermodynamic properties of protein–protein interactions and is becoming a necessary tool for protein–protein complex structural studies. This technique relies upon the accurate measurement of heat changes that follow the interaction of protein molecules in solution, without the need to label or immobilize the binding partners, since the absorption or production of heat is an intrinsic property of virtually all biochemical reactions. ITC provides information regarding the stoichiometry, enthalpy, entropy, and binding kinetics between two interacting proteins. Microscale thermophoresis (MST), is a new method that enables the quantitative analysis of molecular interactions in solution at the microliter scale. The technique is based on the thermophoresis of molecules, which provides information about molecule size, charge and hydration shell. Since at least one of these parameters is typically affected upon binding, the method can be used for the analysis of each kind of biomolecular interaction or modification. The method works equally well in standard buffers and biological liquids like blood or cell-lysate. It is a free solution method which does not need to immobilize the binding partners. MST provides information regarding the binding affinity, stoichiometry, competition and enthalpy of two or more interacting proteins.
== Life == Theodore Ryder was born in Keyport, New Jersey, in 1916. At the age of four, he developed symptoms of diabetes mellitus, including greatly increased urine output, constant, intense thirst and significant weight loss. At that time, no therapy was available to treat diabetes, so the disease would have led to death within a short period of time. The only treatment option was a strict low-carbohydrate low-calorie diet of as little as 500 calories per day, which extended the lives of affected patients by about one to two years. In the spring of 1922, the physicians Frederick Banting and Charles Best at the University of Toronto succeeded in producing insulin purely from extracts of pancreatic tissue. After this became known to Theodore Ryder's family, an uncle who worked as a doctor in New York City attempted to have his nephew included in experiments to test insulin through a personal conversation with Banting. After initial hesitation, Banting gave in and began treating the boy on July 10, 1922, who at that time weighed only 12.5 kilograms at the age of five. Within a few months, Theodore Ryder made a full recovery and became a symbol for the staff treating him of the dramatic successes brought about by insulin. In October of the same year he was able to return home with his mother. In a letter of thanks to Banting he wrote:Dear Dr. Banting, I wish you could come to see me. I am a fat boy now and I feel fine. I can climb a tree. Margaret would like to see you.
Sources: en.wikipedia.org
Dry powder is normally held at -20 degrees Celsius or below in a sealed, light-protected container with desiccant. Brief room-temperature handling during weighing is generally tolerated. Storage instructions vary between suppliers, so the accompanying certificate of analysis should be followed.
Reversed-phase HPLC establishes purity, while mass spectrometry confirms the expected molecular mass. Sequence confirmation may use tandem mass spectrometry or peptide mapping. A certificate of analysis typically reports these results alongside the analytical method applied.
In Russia it is a registered medicine available by prescription. In many other countries it is not approved for human use and is supplied only as a research chemical. Import and possession rules differ by jurisdiction, and buyers are responsible for checking local requirements.
The most common approach combines reverse-phase liquid chromatography with mass spectrometry. Chromatography separates the components while mass spectrometry confirms the molecular mass. Peptide sequencing or tandem mass analysis can further verify the amino acid order.